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Abstract
Background: The shortcomings of clonazepam therapy include tolerance, withdrawal symptoms, and adverse effects 
such as drowsiness, dizziness, and confusion leading to increased risk of falls. Inter-individual variability in the 
incidence of adverse events in patients partly originates from the differences in clonazepam metabolism due to genetic 
and nongenetic factors.
Methods: Since the prominent role in clonazepam nitro-reduction and acetylation of 7-amino-clonazepam is assigned to 
CYP3A and N-acetyl transferase 2 enzymes, respectively, the association between the patients’ CYP3A status (CYP3A5 genotype, 
CYP3A4 expression) or N-acetyl transferase 2 acetylator phenotype and clonazepam metabolism (plasma concentrations of 
clonazepam and 7-amino-clonazepam) was evaluated in 98 psychiatric patients suffering from schizophrenia or bipolar 
disorders.
Results: The patients’ CYP3A4 expression was found to be the major determinant of clonazepam plasma concentrations 
normalized by the dose and bodyweight (1263.5 ± 482.9 and 558.5 ± 202.4 ng/mL per mg/kg bodyweight in low and normal 
expressers, respectively, P < .0001). Consequently, the dose requirement for the therapeutic concentration of clonazepam 
was substantially lower in low-CYP3A4 expresser patients than in normal expressers (0.029 ± 0.011 vs 0.058 ± 0.024 mg/kg 
bodyweight, P < .0001). Furthermore, significantly higher (about 2-fold) plasma concentration ratio of 7-amino-clonazepam 
and clonazepam was observed in the patients displaying normal CYP3A4 expression and slower N-acetylation than all the 
others.
Conclusion: Prospective assaying of CYP3A4 expression and N-acetyl transferase 2 acetylator phenotype can better identify 
the patients with higher risk of adverse reactions and can facilitate the improvement of personalized clonazepam therapy 
and withdrawal regimen.
Keywords: personalized clonazepam therapy, CYP3A4 expression, NAT2 genotype, plasma concentration of 7-amino-
clonazepam
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Introduction
Clonazepam was initially introduced as an antiepileptic agent; 
however, it is a useful therapeutic adjunct in psychiatric disor-
ders (Nardi and Perna, 2006; Mendonca et  al., 2015). It is suc-
cessful in treatment of logorrhea, impulsivity, and grandiosity 
symptoms in patients with bipolar disorders (Moreno et al., 2004). 
In schizophrenia, clonazepam is given to decrease the level of 
agitation, anxiety, and tension or to manage aggression (Bodkin, 
1990). Although the precise mechanism of clonazepam action 
has not been completely clarified, it has been demonstrated that 
the major targets are GABA-A receptors. Clonazepam potenti-
ates the effect of GABA in the brain by increasing the GABAergic 
inhibition (Jenner et al., 1986; Lehoullier and Ticku, 1987). It is 
well tolerated in most of the patients; however, adverse events 
(e.g., drowsiness, dizziness, and confusion) can occur. The seda-
tive effect seems to be more problematic for the elderly than for 
younger patients, because changes associated with aging result 
in greater risk of injuries from falls (Passaro et al., 2000; Pariente 
et al., 2008; Sylvestre et al., 2012). Long-term clonazepam users 
may experience pharmacodynamic tolerance and dependence 
as well as withdrawal symptoms (tremor, dizziness, sweating, 
headache, seizure) following discontinuation of clonazepam 
treatment (Chouinard, 2004; Riss et  al., 2008). The severity of 
withdrawal symptoms appears to be influenced by several fac-
tors, such as the duration of clonazepam therapy, dosage, and 
the rate of drug-tapering.
Clonazepam is extensively metabolized by nitro-reduc-
tion to 7-amino-clonazepam, which is further N-acetylated to 
7-acetamido-clonazepam (Figure 1) (Eschenhof, 1973; Peng et al., 
1984a, 1984b). Hydroxylation of these metabolites and the par-
ent compound to the respective 3-hydroxy metabolites has also 
been reported; however, it is considered to be a minor metabolic 
pathway (Eschenhof, 1973; de Silva and Bekersky, 1974; Knop 
et  al., 1975). In human plasma, the hydroxylated metabolites 
were found to be present at very low concentrations or absent, 
whereas the concentration of 7-amino-clonazepam can be as 
high as or even higher than the concentration of clonazepam 
(Naestoft and Larsen, 1974; Sjö et al., 1975). Although no phar-
macological activity is attributed to 7-amino-clonazepam, it has 
some affinity for benzodiazepine receptor and is able to com-
pete with clonazepam. 7-Amino-clonazepam has been assumed 
to competitively modify the effect of clonazepam on GABA-A 
response and appears to exert mild effects as a partial agonist 
for the GABA-A receptor (Munakata et al., 2008). Furthermore, 
high levels of 7-amino-clonazepam in patients have been asso-
ciated with withdrawal symptoms (Sjö et al., 1975).
Nitro-reduction, the major route of clonazepam metabo-
lism, is catalyzed by CYP3A enzymes (Seree et  al., 1993), 
whereas N-acetyl transferase 2 (NAT2) is responsible for the 
acetylation of 7-amino-clonazepam (Miller et al., 1981; Olivera 
et  al., 2007). CYP3A4 activity displays more than 100-fold 
inter-individual variability (Temesvári et  al., 2012), which is 
partly attributed to genetic factors. CYP3A4*1B allele leads 
to increased transcription; however, the clinical significance 
of CYP3A4*1B to CYP3A4 function is doubtful (Garcia-Martin 
et  al., 2002; Amirimani et  al., 2003). CYP3A4*22 displays low 
hepatic CYP3A4 expression and results in decreased CYP3A4 
activity (Okubo et  al., 2013). Elens et  al. (2013) suggested to 
evaluate the association between CYP3A4*22 and pharma-
cokinetic behavior of CYP3A substrates in combination with 
CYP3A5 genotype. CYP3A5*3 allele results in splicing defect 
and nonfunctional CYP3A5 protein. Those individuals who 
have functional CYP3A5 enzyme are presumed to metabolize 
some CYP3A substrates more rapidly than CYP3A5 nonex-
pressers. Human NAT2 is a polymorphic gene, generally divid-
ing the population into slow and rapid acetylators (McDonagh 
et al., 2014). NAT2*4 is the wild-type allele, responsible for rapid 
acetylator phenotype, whereas NAT2*5, NAT2*6, and NAT2*7, 
the most common alleles in white populations, are defined 
as slow acetylator alleles. The polymorphic CYP3A and NAT2 
alleles may explain some inter-individual differences in blood 
concentrations of clonazepam and 7-amino-clonazepam; 
however, nongenetic factors (hormones, diseases, age, medi-
cation) can modify CYP3A4 activities, resulting in transient 
poor (or extensive) metabolism. The genotype determines the 
potential for the expression of functional or nonfunctional 
CYP enzyme, whereas nongenetic factors give rise to altered 
phenotypes. CYP3A4*1/*1 genotype, predicted to be translated 
to CYP3A4 enzyme with normal function, may be switched 
into poor (or extensive) metabolism due to phenoconversion 
(Shah and Smith, 2015).
Patients’ clonazepam-metabolizing capacity can be esti-
mated by the evaluation of CYP3A status and acetylator pheno-
type. Although CYP3A5 expressers and slow or rapid acetylators 
are simply identified by CYP3A5 and NAT2 genotyping, the 
crucial task is the assessment of hepatic CYP3A4 activity. We 
previously described a complex diagnostic system (CYPtest) 
that determines CYP3A-metabolizing capacity by the current 
CYP3A4 expression in leukocytes. CYP3A4 mRNA levels in leu-
kocytes were proven to inform about the hepatic CYP3A4 activ-
ity (Temesvári et  al., 2012). Patients with CYP3A4*22 allele are 
predicted to display decreased CYP3A4 mRNA levels, which lead 
to permanent low CYP3A4 activity, whereas nongenetic factors 
modifying the expression of functional CYP3A4 gene result in 
transient poor (or extensive) clonazepam metabolism.
Significance Statement
Inter-individual variability in clonazepam metabolism by CYP3A and N-acetyl transferase 2 enzymes was assumed to 
highly contribute to the incidence of adverse reactions. The patients’ CYP3A4 expression was found to be the major 
determinant of clonazepam plasma concentrations, whereas CYP3A5 genotype and N-acetyl transferase 2 acetylator 
phenotype did not influence the steady-state levels of clonazepam. Therefore, CYP3A4 expression-guided clonazepam 
dosing (0.029 mg/kg for low expressers and 0.058 mg/kg for normal expressers) was proposed for achieving the optimal 
plasma concentrations. Furthermore, normal CYP3A4 expression and slow N-acetyl transferase 2 acetylator phenotype 
evoking high plasma concentration ratio of 7-amino-clonazepam and clonazepam may account for low efficacy or 
withdrawal symptoms of clonazepam. Prospective assaying of CYP3A4 expression and N-acetyl transferase 2 acetylator 
phenotype can better identify the patients with higher risk of adverse reactions and facilitate the improvement of 
personalized clonazepam therapy and withdrawal regimen.
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Information on patients’ CYP3A status and NAT2 genotype 
can refine the personalized clonazepam therapy, facilitating the 
appropriate dosage, and can predict the risk of high blood lev-
els of 7-amino-clonazepam requiring more prudent withdrawal 
strategy for psychiatric patients. The goals of the present work 
were to investigate the patients’ CYP3A status predicting poten-
tial poor or extensive clonazepam metabolism and to analyze 
the influence of CYP3A4 expression on clonazepam blood con-
centrations and patients’ dose requirements. We attempted to 
provide evidence that CYP3A5 and CYP3A4 genotypes are not the 
only determinant factors in CYP3A metabolizer status, but the 
expression rate of CYP3A4 gene can highly influence a patient’s 
CYP3A-metabolizing capacity.
Methods
Patients and Study Design
Inpatients (n = 98) diagnosed with schizophrenia, schizoaffec-
tive, or bipolar disorders at the Department of Psychiatry and 
Psychotherapy, Semmelweis University (Budapest, Hungary) 
were enrolled. The patients on stable clonazepam therapy for 
at least 1 week were included in the study. Written informed 
consent was obtained from all participants. The study was 
approved by the Hungarian Committee of Science and Ethics. 
It was performed under the regulation of Act CLIV of 1997 on 
Health and the decree 23/2002 of the Minister of Health of 
Hungary and in accordance with the declaration of Helsinki.
The patients’ demographic data as well as the details 
of medication were recorded (Table  1). All of the patients 
belonged to the Caucasian white population. The patients’ 
psychotropic therapy generally included antipsychotics (que-
tiapine, olanzapine, aripiprazole, clozapine, risperidone, or 
haloperidol), mood stabilizers (valproic acid, lamotrigine, 
carbamazepine, lithium), and, if necessary, antidepressants 
(fluoxetine, paroxetine, bupropion, or venlafaxine) or seda-
tives (zopiclone or zolpidem). The clonazepam therapy was 
applied according to the conventional clinical protocol, initi-
ated at low dosage (0.5 mg/d), and subsequently titrated until 
optimal clinical response was achieved (0.5–6.5 mg/d), gener-
ally within 5 days. In urgent cases when agitation, aggression, 
or mania had to be managed, higher initial doses were admin-
istered. Clonazepam dosage was recorded for 1 week before 
blood sampling for testing patients’ CYP3A status and NAT2 
genotype and for drug assay.
Assaying CYP3A Status and NAT2 Genotype
Patients’ CYP3A status was characterized by CYP3A5 genotyping 
and assaying CYP3A4 expression in leukocytes. Genomic DNA 
Figure 1. Metabolic pathways of clonazepam.
Table 1. Patients’ Demographic Characteristics
Patients’ Demographic 
Data
Number 98
Gender (male, female) m: 39 f: 59
Age (y)a 43 (19; 70)
Bodyweight (kg)a 73.7 (61.25; 87)
Primary disease Schizophrenia 47
Schizoaffective 
disorder
33
Bipolar disorder 18
Clonazepam dosea (mg/d) 2 (0.5; 6.5)
(mg/bodyweight) 0.02667 (0.0023; 0.12)
Co-medication Aripiprazole 10
Clozapine 12
Haloperidol 21
Olanzapine 40
Quetiapine 28
Risperidone 34
Carbamazepine 4
Lamotrigine 5
Lithium 16
Valproic acid 22
Bupropion 5
Fluoxetine 2
Paroxetine 5
Venlafaxine 2
Zolpidem 6
Zopiclone 1
aMedian (min; max).
 by guest on January 16, 2017
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
4 | International Journal of Neuropsychopharmacology, 2016
Copyedited by: oup
and leukocytes were isolated from the peripheral blood samples 
according to the methods described by Temesvári et al. (2012). 
CYP3A5 genotyping was carried out by hydrolysis single nucleo-
tide polymorphism analysis for CYP3A5*3 using TaqMan probes 
(BioSearch Technologies, Novato, CA). Genetic polymorphisms of 
CYP3A4 are assumed to influence CYP3A4 expression (Garcia-
Martin et al., 2002; Amirimani et al., 2003; Okubo et al., 2013); 
thus, CYP3A4 genotype for CYP3A4*1B and CYP3A4*22 alleles 
was also assayed by hydrolysis single nucleotide polymorphism 
analysis using TaqMan probes (BioSearch Technologies).
For CYP3A4 expression, total RNA was extracted from leuko-
cytes, RNA (3 μg) was reverse transcribed into single-stranded 
cDNA using the Maxima First Strand cDNA Synthesis Kit 
(Thermo Scientific, Waltham, MA), and then real-time PCR with 
human cDNA was performed using KAPA Fast Probes Mastermix 
(KAPA Biosystems, Cape Town, South Africa) and UPL probe for 
CYP3A4 (Roche Diagnostics GmbH, Mannheim, Germany). The 
quantity of CYP3A4 mRNA relative to that of the housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase was deter-
mined. Three categories of CYP3A4 expression were applied to 
describe low, normal, and high expressers. The cut-off values 
for the CYP3A4 mRNA levels in leukocytes have been previously 
established on the basis of the cut-off values for the hepatic 
CYP3A4 activities (nifedipine oxidation or midazolam 1’- and 
4-hydroxylation) (Temesvári et  al., 2012). Low expressers dis-
played a ratio of CYP3A4/glyceraldehyde 3-phosphate dehydro-
genase <10–6, normal expressers a ratio between 10–6 and 10–4, 
whereas high expressers a ratio >10–4. The patients were sorted 
by the CYP3A5 genotype and by CYP3A4 expression. Those sub-
jects who carry at least one CYP3A5*1 allele were considered 
to be CYP3A5 expressers, while those with CYP3A5*3/*3 geno-
type were CYP3A5 nonexpressers. By the CYP3A4 mRNA levels, 
they were assigned to low, normal, and high CYP3A4 expresser 
categories.
NAT2 acetylation phenotype was inferred from the 4-SNP 
panel of 191G>A (rs1801279), 341C>T (rs1801280), 590G>A 
(rs1799930), and 857G>A (1799931), distinguishing the slow 
acetylator NAT2*5, NAT2*6, NAT2*7, and NAT2*14 alleles from the 
rapid acetylator alleles (Doll and Hein, 2001; Hein and Doll, 2012). 
Patients with 2 slow acetylator alleles were assigned to the slow 
acetylator phenotype category, whereas all the others were con-
sidered to display rapid/intermediate acetylator phenotype.
Blood Concentrations of Clonazepam and  
7-Amino-Clonazepam
The blood samples were taken 12 hours after the evening dose of 
clonazepam. The steady-state concentrations of clonazepam and 
7-amino-clonazepam were determined by liquid chromatogra-
phy coupled with tandem mass spectrometry. Chromatographic 
separation was performed using an Inertsil ODS-4 (75 × 2.1 mm, 
3 μm) column (GL Sciences Inc., Tokyo, Japan) and mobile phases 
of acetonitrile and 0.1% formic acid in gradient running mode. 
The samples were analyzed using positive electrospray ioniza-
tion and multiple reaction monitoring mode for quantitation of 
the parent compound and its metabolite. The following transi-
tions were used: 316/270 (m/z), 316/214 (m/z) for clonazepam 
and 286/222 (m/z), 286/121 (m/z) for 7-amino-clonazepam. 
The assay range was 1 to 100 ng/mL for both clonazepam and 
7-amino-clonazepam. The intra- and inter-day variability for 
the quantification was <10%. Normalized blood levels of clon-
azepam were calculated by dividing the concentration values by 
the corresponding 24-h dose on a mg/kg bodyweight basis and 
expressed as (ng/mL) × (mg dose/kg bodyweight)-1.
Data Analysis
Statistical significance of demographic data, CYP3A4 expres-
sion, NAT2, and CYP3A5 genotypes as covariates of clon-
azepam and 7-amino-clonazepam concentrations was 
analyzed by ANOVA using linear model of covariate effects 
with constant terms. Several mathematical models (nonlin-
ear Artificial Neuronal Network and linear with various input 
combinations) were tested to identify the key factor(s) in 
steady-state clonazepam concentrations; however, the best 
models for the optimal prediction with the smallest stand-
ard deviation of model prediction and the smallest number of 
model parameters were all linear. The dose, bodyweight, and 
CYP3A4 expression were identified as significant parameters 
for clonazepam plasma concentration (P < .0005), whereas 
clonazepam plasma concentration, CYP3A4 expression and 
NAT2 genotype were identified as significant parameters for 
7-amino-clonazepam (P < .005). However, for 7-amino-clon-
azepam, only the combination of normal CYP3A4 express-
ers and slow NAT2 metabolizers formed a group with slower 
pharmacokinetics and therefore higher 7-amino-clonazepam 
plasma concentrations.
The statistical model for the clonazepam plasma concentra-
tion based on ANOVA analysis and for the effects of dose and 
bodyweight on the concentration is therefore defined as:
c k
dose
bw
kclo = +1 0* ,
where cclo is clonazepam predose plasma concentration 
expressed as ng/mL, dose is clonazepam dose in mg, and bw is 
bodyweight in kg. Model parameters k0 and k1 were estimated 
for low and normal or high CYP3A4 expressers individually. The 
statistical model for the 7-amino-clonazepam plasma concen-
tration based on ANOVA analysis is defined as:
c k c kamino clo clo7 1 0- - = +* ,
where c7-amino-clo is 7-amino-clonazepam plasma concentration 
(ng/mL) and cclo is clonazepam plasma concentration (ng/mL). 
Model parameters k0 and k1 were estimated individually for 2 
groups. The first group comprised all low CYP3A4 expressers 
regardless of the NAT2 phenotype and normal/high CYP3A4 
expressers in combination with rapid NAT2 metabolizers. In the 
second group, the patients were normal/high CYP3A4 express-
ers and slow NAT2 acetylators. Linear regression was used to 
estimate the model parameters k1 and k0. Residual error of both 
models was used to estimate the model precision. To estimate 
optimal dose, the model for clonazepam plasma concentration 
was resolved for the dose:
dose bw
c k
k
clo= -* ( ) .0
1
The lower and upper limits for the optimal dose were esti-
mated from the lower and upper limits of the optimal clon-
azepam plasma concentration range of 20 to 70 ng/mL. Matlab 
R2009b was used to perform the analysis and calculate the 
optimal dosing.
For statistical analysis, the data of normalized clonazepam 
plasma concentrations, the 7-amino-clonazepam:clonazepam 
ratio, and the dose requirements for the optimal therapeutic 
level in the patients assigned to various CYP3A4 expression were 
expressed as the mean ± SD. Between-group differences were cal-
culated by the use of Kruskal-Wallis ANOVA followed by Mann-
Whitney comparison test. P < .05 was considered statistically 
significant.
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Results
Patients’ Drug-Metabolizing Capacity and 
Clonazepam Exposure
Most of the patients involved in the study were identified as 
CYP3A5 nonexpressers (CYP3A5*3/*3) and were thus expected 
to lack of functional CYP3A5 enzyme (Table  2). Eight patients 
carrying CYP3A5*1/*3 heterozygous genotypes were considered 
to be CYP3A5 expressers. The frequency of CYP3A5*3 allele in 
the patients (91.8%) was similar to that in Caucasian (white) 
populations (88–97%) (Kurose et al., 2012; Zanger and Schwab, 
2013). For the categorization of the patients regarding CYP3A4 
expression, more reliable results were obtained from CYP3A4 
mRNA measurements than from CYP3A4 genotyping. One-
fifth of the patients carried expression-altering mutations in 
CYP3A4 gene (CYP3A4*1B or CYP3A4*22); 3 of the 98 patients 
carried CYP3A4*1/*1B genotype, and 17 carried CYP3A4*1/*22 
(homozygous mutant CYP3A4 genotypes were not identified 
in the patients) (Table  2). However, we could not demonstrate 
any association between CYP3A4 genotype and CYP3A4 expres-
sion. The ratio of low and normal CYP3A4 expressers among 
the patients with CYP3A4*1/*1B or CYP3A4*1/*22 genotypes were 
similar to those carrying CYP3A4*1/*1. CYP3A4 expression assays 
revealed that about three-fourths of the patients expressed 
CYP3A4 at normal level, >20% were low CYP3A4 expressers, and 
only 1 patient displayed high CYP3A4 expression (Table 2). The 
patients’ demographic parameters may explain the variability of 
CYP3A4 expression; however, no association was found between 
the gender or age and CYP3A4 mRNA levels. Since psychiatric 
patients are often under multi-drug therapy, co-medication is 
a potential factor that can modify CYP3A4 function. The major-
ity of the psychotropic agents administered to the patients 
involved in the present study are primarily metabolized by 
CYP2D6, CYP2B6, or CYP1A2 (aripiprazole, clozapine, haloperi-
dol, olanzapine, quetiapine, risperidone, lamotrigine, bupropion, 
fluoxetine, paroxetine, venlafaxine) or by non-CYP enzymes 
(valproic acid). The CYP3A4 inducer carbamazepine included in 
the therapeutic regimen of 4 patients can potentially increase 
CYP3A4 expression (Lai et al., 1978; Spina et al., 1996); however, 
these patients still expressed CYP3A4 at low or normal level. The 
CYP3A4 substrates zolpidem and zopiclone were not applied 
regularly, but in case of need.
NAT2 acetylator phenotype discrimination by 4-SNP panel 
recommended for accurate assignment of NAT2 alleles (Hein 
and Doll, 2012) identified 341T>C and 590G>A as the most fre-
quent SNPs (34.7% and 35.7, respectively), whereas the fre-
quency of 857G>A was merely 2.04% and 191G>A did not occur 
at all. Of 98 patients, 52 were assigned to the slow acetylator 
phenotype category and 46 were considered to be NAT2 rapid or 
intermediate acetylator (Table 2).
The present study evaluated the association between the 
patients’ drug-metabolizing capacity (CYP3A4 expression, 
CYP3A5 genotype, NAT2 acetylator phenotype) and their 
clonazepam therapy (dose or dose/bodyweight, clonazepam 
plasma levels), which can contribute to the improvement 
of patients’ personalized medication. The patients’ CYP3A5 
genotype and NAT2 acetylator phenotype seemed to have 
no effect on clonazepam plasma concentrations, whereas 
CYP3A4 expression significantly influenced the steady-state 
levels of clonazepam. The models required clonazepam dose 
divided by the patients’ bodyweight for the optimal prediction. 
For the patients expressing CYP3A4 at low and normal levels, 
2 separate models were constructed with the same equation 
but with different values of parameters (k0 and k1, Figure 2a). 
The models were able to predict clonazepam plasma concen-
trations with SDs of 6.2 and 6.7 ng/mL for low and normal 
expressers, respectively.
The statistical analysis displayed significant association 
between the patients’ CYP3A4 expression and the stable plasma 
concentrations of clonazepam normalized by the dose and the 
patient’s bodyweight. The normalized concentrations of clonaz-
epam were significantly higher in the patients displaying low 
CYP3A4 mRNA levels (1263.5 ± 482.9 ng/mL per mg/kg body-
weight) than normal CYP3A4 expressers (558.5 ± 202.4 ng/mL per 
Figure  2. Influence of the patients’ CYP3A4 expression on clonazepam plasma concentrations. (a) Linear models for low (triangles) and normal (points) CYP3A4 
expresser patients, and (b) clonazepam concentrations normalized by dose and bodyweight in the patients expressing CYP3A4 at low, normal, and high levels. Black 
triangles indicate patients carrying CYP3A5*1. *P < .0001.
Table 2. Patients’ CYP3A Status and NAT2 Acetylator Phenotype
n %
CYP3A Status
 CYP3A5 genotype CYP3A5 expresser (CYP3A5*1/*3) 8 8.2
CYP3A5 nonexpresser (CYP3A5*3/*3) 90 91.8
 CYP3A4 genotype CYP3A4*1/*1 78 79.6
CYP3A4*1/*1B 3 3.1
CYP3A4*1/*22 17 17.3
 CYP3A4 expression Low 22 22.4
Normal 75 76.5
High 1 1.02
NAT2 Phenotype
Slow acetylator 52 53.1
Rapid/intermediate acetylator 46 46.9
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mg/kg bodyweight) (P < .0001) (Figure 2b). The normalized clon-
azepam concentration in the patient expressing CYP3A4 at high 
level (452.6 ng/mL per mg/kg bodyweight) was comparable with 
those in the normal expresser patients.
Optimization of Clonazepam Dose
According to the clinical practice, clonazepam plasma concen-
trations ranging between 20 and 70 ng/mL are considered to 
be therapeutically optimal in the management of anxiety and 
tension in schizophrenic patients or impulsivity and grandios-
ity symptoms in patients with bipolar disorders (Hiemke et al., 
2011). The 2 models for prediction of clonazepam plasma con-
centration in patients expressing CYP3A4 at low or normal levels 
had comparable prediction quality (Figure 2a) and were found to 
be applicable for prediction of optimal dosing. The dose require-
ment for therapeutic plasma concentration was predicted for 
each patient setting the minimal dose adjustment to 0.5 mg, 
because the lowest content of clonazepam products available 
is 0.5 mg (Figure 3a). The models proposed significantly higher 
daily dose of clonazepam for the patients expressing CYP3A4 at 
normal level than for those with low CYP3A4 mRNA level (the 
dose range of 4.47–7.84 mg vs 2.23–4.22 mg, P < .0001), whereas 
the dosage applied in the clinical practice was considered to 
be the same for low and normal CYP3A4 expresser patients 
(2.28 ± 1.56 mg vs 2.47 ± 1.58 mg, P = .5237). The clonazepam daily 
dose applied for the patients was found to be out of the dose 
range predicted from the models in about 70% of the patients, 
that is, most of the patients were misdosed. Underdosing 
occurred more frequently, primarily in the patients expressing 
CYP3A4 at normal level (Figure 3a). Moreover, the routine dos-
ing regimen appears to be appropriate for the patients with low 
CYP3A4 mRNA levels rather than for normal expressers. Of 22 
low expresser patients, only 9 were misdosed (3 overdosed and 
6 underdosed), whereas the clonazepam therapy of 13 patients 
(about 60%) in the low CYP3A4 expresser group resulted in 
therapeutic plasma concentrations of clonazepam. The math-
ematical model displayed clonazepam dosing to be optimal for 
only 15 patients (20%) in the normal CYP3A4 expresser group 
(n = 76), although the plasma concentrations were in the thera-
peutic range in 25 normal expresser patients. Therefore, we took 
a different approach for the calculation of clonazepam dose 
requirement, and we inferred from the dosing applied for those 
patients who displayed plasma concentrations in the range 
of 20 to 70 ng/mL (Figure  3b). The patients expressing CYP3A4 
mRNA at low levels required significantly lower dose of clonaze-
pam for the optimal plasma level than normal CYP3A4 express-
ers. The dose requirement was approximately 50% lower for the 
low CYP3A4 expresser patients (0.029 ± 0.011 mg/kg bodyweight) 
than for the patients in the normal CYP3A4 expresser group 
(0.058 ± 0.024 mg/kg bodyweight) (P < .0001) (Figure 3b).
7-Amino-Clonazepam Concentration in Patients 
with Various Drug-Metabolizing Capacity
CYP3A4 catalyzes the formation of 7-amino-clonazepam, and 
NAT2 is involved in the N-acetylation of 7-amino-clonazepam. 
Thus, the role of the patients’ CYP3A4 expression and NAT2 
acetylator phenotype in the plasma concentrations of 7-amino-
clonazepam was evaluated. The patients were divided into 4 
groups according to the CYP3A4 expression (low and normal/
high) and NAT2 phenotype (slow and rapid/intermediate). 
Significantly higher (about 2-fold higher) plasma concentration 
ratio of 7-amino-clonazepam and clonazepam was observed in 
the patients displaying normal CYP3A4 expression and slow 
N-acetylation than in all the others (Figure 4a). However, mod-
eling of the association between the patients’ CYP3A4 expres-
sion or N-acetylator phenotype and plasma concentrations of 
7-amino metabolite identified 2 cohorts. The first group con-
sisted of the patients who expressed CYP3A4 mRNA at normal/
high level and displayed slow NAT2 acetylator phenotype. The 
remaining 3 combinations (low CYP3A4 expressers with any 
acetylator phenotype, normal/high CYP3A4 expressers with 
rapid/intermediate acetylator phenotype) were grouped, since 
the separate models for these combinations did not result in sig-
nificantly different parameters. The same model was applied for 
the 2 groups; however, the model parameter values were different 
(Figure 4b). The models were able to predict the plasma concen-
trations of 7-amino-clonazepam with the SDs of 4.5 and 4.9 ng/
mL for the normal CYP3A4 expressers with slow N-acetylation 
phenotype and the rest of the patients, respectively.
Figure 3. Influence of the patients’ CYP3A4 expression on clonazepam dose requirements. (a) Dose requirements for therapeutic concentration of clonazepam calcu-
lated from the models (bars) and applied clonazepam doses (points) in normal and low CYP3A4 expresser patients, and (b) dose requirements calculated from applied 
doses in the patients displaying therapeutic concentrations of clonazepam. * P < .0001.
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Discussion
Clonazepam is extensively metabolized, and <2% of the admin-
istered dose is eliminated as unchanged parent compound. 
Although the plasma concentration in patients seems to be 
strongly influenced by their clonazepam-metabolizing capacity 
and the therapeutic drug monitoring for clonazepam is consid-
ered to be useful (Hiemke et al., 2011), it is not a routine clinical 
practice in psychiatry. The primary role of CYP3A4 enzyme in 
clonazepam biotransformation has been verified (Seree et  al., 
1993), but the dosing strategy applied in clinical practice does 
not take the patient’s hepatic CYP3A4 activity into consid-
eration. According to our results, low CYP3A4 expression was 
accompanied with significantly higher plasma concentrations 
of clonazepam. Age-related decline in CYP-mediated drug 
metabolism is well known (Tanaka, 1998); thus, a higher ratio of 
low CYP3A4 expressers is expected in geriatric population than 
in younger adults. Misdosing of low expresser patients results 
in an overexposure to clonazepam, which can eventually lead 
to an increased risk of side effects. Side effects, such as drowsi-
ness, ataxia, and dizziness, have been reported to develop in 
the majority of cases for plasma concentrations >60 ng/mL, and 
toxic effects increase in severity for levels >100 ng/ml (Morselli 
and Franco-Morselli, 1980). Since clonazepam can cause gait 
and balance disturbances, increased risk of falling is expected 
in the patients displaying low CYP3A4 expression, for example, 
in the elderly population. Several authors have indicated that 
benzodiazepine therapy is a potential risk factor for injurious 
falls in elders (Ray et al., 2000; Souchet et al., 2004; Pariente et al., 
2008). Ray et  al. (2000) demonstrated an association between 
the use of benzodiazepines with long elimination half-lives 
(e.g., clonazepam) and increased risk of falls, whereas Herings 
et  al. (1995) reported significantly higher incidence of falls in 
patients exposed to high doses of benzodiazepines. Sylvestre 
et al. (2012) suggested benzodiazepine-specific analysis, because 
the mechanisms influencing the risk of falls differ across ben-
zodiazepines. For clonazepam, the duration of past treatment 
was found to be a more important risk factor over the dose. 
Estrin et al. (2009) suggested a fall prevention program at psy-
chiatric hospitals to identify patients at high risk of falling. Our 
present work provided clear evidence for that the inter-indi-
vidual variability in clonazepam metabolism can be estimated 
by the analysis of patients’ CYP3A4 expression. The oral clear-
ance of clonazepam was observed to be significantly higher in 
the patients expressing CYP3A4 at a normal or high level than 
in low CYP3A4 expressers; thus, one-half of the doses needed 
for low expressers as for normal/high CYP3A4 expressers to 
maintain the target therapeutic concentrations of clonazepam. 
CYP3A4-phenotyping can contribute to the identification of 
high-risk patients and advances the rationalization of clonaz-
epam therapy.
The plasma concentration of the main metabolite, 7-amino-
clonazepam, is often comparable with the concentration of clon-
azepam, and a considerable amount is also present in the brain. 
7-Amino-clonazepam is considered to be pharmacologically 
inactive; however, Munakata and Tsuchiya (2008) have demon-
strated that it is a weak partial agonist for GABA-A receptor, and 
it can competitively modify the effect of clonazepam. 7-Amino 
metabolite of clonazepam at a high concentration might sig-
nificantly compete to occupy benzodiazepine-binding sites and 
cause a more rapid decrease of clonazepam binding when the 
concentration decreases after discontinuation of clonazepam 
therapy. Therefore, clinical consequences may be anticipated 
for the patients with high levels of 7-amino-clonazepam dur-
ing clonazepam withdrawal. According to our findings, normal/
high CYP3A4 expression and slow NAT2 acetylator phenotype 
appear to predict high plasma concentrations of 7-amino-clon-
azepam. While the rate of primary metabolism of clonazepam 
is influenced by CYP3A4 activity, the plasma concentration of 
7-amino-clonazepam depends on CYP3A4 and NAT2 acetylator 
phenotype, and the slow acetylation rate can obviously explain 
the accumulation of the primary metabolite. Since most of the 
patients (77.5% in this study) expressed CYP3A4 at normal/high 
level and approximately one-half of the patients were slow acet-
ylators, high plasma concentrations of 7-amino-clonazepam 
were anticipated in 35% to 40% of patients (38/98 in this study). 
Furthermore, patients with high 7-amino-clonazepam levels 
have been found to display withdrawal symptoms (Sjö et  al., 
1975). A careful and protracted withdrawal regimen can be sug-
gested to apply for normal CYP3A4 expresser patients with slow 
NAT2 acetylator phenotype to avoid withdrawal symptoms or to 
minimize the severity of symptoms. Nardi et al. (2010) recom-
mended a 0.25-mg/wk rate of dosage reduction after intermedi-
ate-term use of clonazepam; however, the potential benefits of 
personalizing discontinuation are worthy of investigation.
In conclusion, the patients’ CYP3A4 expression generally 
influenced by nongenetic factors was found to be the major 
determinant of clonazepam plasma concentration normal-
ized by the dose and bodyweight; thus, prospective assaying 
of patients’ CYP3A4 expression can identify poor metabolizers 
with higher risk of side effects, including dizziness and injurious 
Figure 4. Influence of the patients’ CYP3A4 expression and N-acetyl transferase 2 (NAT2) acetylator phenotype on the concentration ratio of 7-amino-clonazepam and 
clonazepam. (a) 7-Amino-clonazepam/clonazepam concentrations in patients with various CYP3A4 expression and NAT2 acetylator phenotype, and (b) linear models 
for normal CYP3A4 expresser slow NAT2 acetylator patients (triangles) and for the others (points). R/I rapid and intermediate NAT2 acetylators, *P < .0001.
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falls. CYP3A4 expression guided refinement of clonazepam 
therapy can contribute to the avoidance of misdosing-induced 
side effects in patients. The plasma concentrations of 7-amino-
clonazepam metabolite were found to be associated with the 
patients’ CYP3A4 expression and NAT2 acetylator phenotype. 
The knowledge of patients’ CYP3A4 expression and NAT2 acet-
ylator phenotype may improve the clonazepam withdrawal 
regimen. Tailored medication controlled by patients’ CYP3A4 
expression and NAT2 phenotype can facilitate the improvement 
of the individual clonazepam therapy, leading to the dosage opti-
mization for a more effective therapy and minimizing the risk 
of side effects and withdrawal symptoms. Further prospective 
studies evaluating the clinical outcome are warranted to deter-
mine the efficacy, safety, and risk/benefit of CYP3A4 and NAT2 
guided clonazepam therapy over conventional clinical practice.
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